Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19

References

• WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020 [Internet]. [ cited March 12, 2022]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-The-media-briefing-on-2019-ncov-on-11-february-2020. Accessed August 18, 2022.
   Google Scholar
• Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154. doi:10.1038/s41579-020-00459-7.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Rzymski P, Zarębska-Michaluk D, et al. Demographic and clinical overview of hospitalized COVID-19 patients during the first 17 months of the pandemic in Poland. J Clin Med. 2021;11(1):117. doi:10.3390/jcm11010117
   PubMed Web of Science ®Google Scholar
• ArcGIS Dashboards [Internet]; [ cited March 12, 2022]. Available from: https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf. Accessed August 18, 2022.
   Google Scholar
• Ko JY, Danielson ML, Town M, et al. Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis. 2021;72(11):E695–703. doi:10.1093/cid/ciaa1419
   PubMed Web of Science ®Google Scholar
• Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021;16(3):e0247461. doi:10.1371/journal.pone.0247461
   PubMed Web of Science ®Google Scholar
• Tsukada N, Inamura J, Igarashi S, Sato K. 血液悪性疾患患者におけるCOVID-19院内発症例の重症化リスクの検討[A retrospective analysis of risk factors for severity of nosocomial COVID-19 in patients with hematological malignancy]. Rinsho Ketsueki. 2021;62(10):1474–1481. [ Japanese]. doi:10.11406/rinketsu.62.1474.
   PubMedGoogle Scholar
• Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–45. doi:10.1016/S2352-3026(20)30251-9
   PubMed Web of Science ®Google Scholar
• Chober D, Aksak W, Bobrek-Lesiakowska K, et al. Effectiveness of tocilizumab in patients with severe or critical lung involvement in COVID-19: a retrospective study. J Clin Med. 2022;11(9):2286. doi:10.3390/jcm11092286
   PubMed Web of Science ®Google Scholar
• Chober D, Aksak-Wąs B, Niścigorska-Olsen J, Niekrasz M, Parczewski M. Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study. Biomedicines. 2022;10(7):1581. doi:10.3390/biomedicines10071581
   Google Scholar
• Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222(7):1103–1107. doi:10.1093/infdis/jiaa446
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303. doi:10.1056/NEJMoa1910993.
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi:10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi:10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2021;27(2):387–389. doi:10.1016/j.jiac.2020.12.001
   PubMed Web of Science ®Google Scholar
• Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: an overview. Eur J Pharmacol. 2020:889. Available from:, https://pubmed.ncbi.nlm.nih.gov/33053381/.
   Google Scholar
• Chen LYC, Quach TTT. COVID-19 cytokine storm syndrome: a threshold concept. Lancet Microbe. 2021;2(2):e49–50. doi:10.1016/S2666-5247(20)30223-8.
   PubMedGoogle Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final Report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a Phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209–221. doi:10.1016/S1473-3099(21)00485-0
   PubMed Web of Science ®Google Scholar
• Olender SA, Perez KK, Go AS, et al. Remdesivir for severe Coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis. 2021;73(11):E4166–74. doi:10.1093/cid/ciaa1041
   PubMed Web of Science ®Google Scholar
• Garibaldi BT, Wang K, Robinson ML, et al. Real-world effectiveness of remdesivir in adults hospitalized with Coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study. Clin Infect Dis. 2021; doi:10.1093/cid/ciab1035/6463010.
   PubMedGoogle Scholar
• Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV-2 infection: recommendations of the Polish association of epidemiologists and infectiologists as of March 31, 2020. Pol Arch Intern Med. 2020;130(4):352–357. doi:10.20452/pamw.15270
   PubMedGoogle Scholar
• Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV-2 infection: recommendations of the Polish association of epidemiologists and infectiologists. Annex no. 1 as of June 8, 2020. Pol Arch Intern Med. 2020;130(6):557–558. doi:10.20452/pamw.15424
   PubMedGoogle Scholar
• Flisiak R, Parczewski M, Horban A, et al. Management of SARS-CoV-2 infection: recommendations of the Polish association of epidemiologists and infectiologists. Annex no. 2 as of October 13, 2020. Pol Arch Intern Med. 2020;130(10):915–918. doi:10.20452/pamw.15658
   PubMedGoogle Scholar
• Ramasamy S, Subbian S. Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis. Clin Microbiol Rev. 2021;34(3):51.
   Web of Science ®Google Scholar
• Qu J, Sumali B, Lee H, et al. Finding of the factors affecting the severity of COVID-19 based on mathematical models. Sci Rep. 2021;11(1):. doi:10.1038/s41598-021-03632-x
   Web of Science ®Google Scholar
• Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol. 2021:897. Available from: https://pubmed.ncbi.nlm.nih.gov/33549577/.
   Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807. doi:10.1056/NEJMoa2031994
   PubMed Web of Science ®Google Scholar
• Flisiak R, Zarębska-Michaluk D, Berkan-Kawińska A, et al. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study. Pol Arch Intern Med. 2021;131(1):103–110. doi:10.20452/pamw.15735
   PubMedGoogle Scholar
• Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194(7):E242–51. doi:10.1503/cmaj.211698
   PubMed Web of Science ®Google Scholar
• Bistrovic P, Manola S, Papic I, Jordan A, Ortner Hadziabdic M, Lucijanic M. Atrial fibrillation in COVID-19 patients receiving remdesivir, matched case-control analysis. Am J Emerg Med. 2022;59:182–183. doi:10.1016/j.ajem.2022.04.051
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Cikara T, Bistrovic P, et al. Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis. J Infect. 2022;85(2):174–211. doi:10.1016/j.jinf.2022.04.045
   PubMed Web of Science ®Google Scholar
• Siemieniuk RAC, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;3:370.
   Google Scholar
• Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology. 2020;35(5):288. doi:10.1152/physiol.00019.2020
   PubMed Web of Science ®Google Scholar
• Goubet AG, Dubuisson A, Geraud A, et al. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ. 2021;28(12):3297–3315. doi:10.1038/s41418-021-00817-9
   PubMed Web of Science ®Google Scholar
• Altamirano-Molina M, Pacheco-Modesto I, Amado-Tineo J. Prolonged viral shedding of SARS-CoV-2 in patients with acute leukemia. Hematol Transfus Cell Ther. 2022;44(2):299–300. doi:10.1016/j.htct.2021.11.017.
   PubMedGoogle Scholar
• Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183(7):1901–1912.e9. doi:10.1016/j.cell.2020.10.049
   PubMed Web of Science ®Google Scholar
• Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223(1):23–27. doi:10.1093/infdis/jiaa666
   PubMed Web of Science ®Google Scholar
• Diaz GA, Christensen AB, Pusch T, et al. Remdesivir and mortality in patients with COVID-19. Clin Infect Dis. 2021; Available from https://pubmed.ncbi.nlm.nih.gov/34409431/.
   Google Scholar
• Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8) doi:10.1002/14651858.CD014962
   PubMed Web of Science ®Google Scholar
• Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine. 2021;71(1):3. doi:10.1007/s12020-020-02536-6
   PubMed Web of Science ®Google Scholar
• Samadizadeh S, Masoudi M, Rastegar M, Salimi V, Shahbaz MB, Tahamtan A. COVID-19: why does disease severity vary among individuals? Respir Med. 2021;180:106356. doi:10.1016/j.rmed.2021.106356
   PubMed Web of Science ®Google Scholar
• Živković NP, Lucijanić M, Bušić N, et al. The associations of age, sex, and comorbidities with survival of hospitalized patients with coronavirus disease 2019: data from 4014 patients from a tertiary-center registry. Croat Med J. 2022;63(1):36–43. doi:10.3325/cmj.2022.63.36
   PubMed Web of Science ®Google Scholar